Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Phil Cressman who wrote (2549)	12/23/1999 2:30:00 PM
From: Walter Morton	Respond to of 2742

Well we are back down to normal volume. Maybe it was the market makers playing with larger volume.

To: Phil Cressman who wrote (2549)	2/2/2000 3:51:00 PM
From: Walter Morton	Read Replies (1) \| Respond to of 2742

Phil, have you sold all of your CIST? Does that previous post give you the impression that CIST has made some progress regarding CIST's agreement with Pasteur Meriux Connaught, a subsidiary of Aventis (NYSE:AVE)(formerly known as Rhone-Pouleno Group (NYSE: RP))? The merger of France's Rhone-Poulenc and Germany's Hoechst created Aventis and displaced Merck as the #1 pharmaceutical company in terms of revenue: cbs.marketwatch.com